Motus GI Holdings Inc (NASDAQ:MOTS) Stock Surges After Positive Topline Data

Every morning investors check the action in the premarket trading period in order to get an idea about the rest of the day’s action and this morning many might have noticed the premarket period rally in the Motus GI Holdings Inc (NASDAQ:MOTS) stock.

Trading Data

On Tuesday, MOTS stock fell 7.21% to $0.2575 with more than 803K shares, compared to its average volume of 570K shares. The stock moved within a range of $0.2525 – 0.2750 after opening trade at $0.2670.

Motus GI Announces Positive Topline Data From EU Study of the Pure-Vu System in Hard-to-Prepare Patients Presented at Digestive Disease Week 2022

The medical technology company has come into significant focus among investors and managed to clock gains of as much as 45% in the premarket trading period. As it happens, the company was in fact in the news yesterday after it announced positive top-line data with regards to its Pure-Vu system in a European Union study initiated by an investigator.

See Why This OTC Fintech Stock May Have Investors Seeing Green

In addition to that, it is also necessary to point out that the data had also been presented by Motus in a poster at the Digestive Disease Week for 2022. In the report it was noted that the Pure-Vu system had been successful in boosting the adequate cleansing rate to a staggering 97.7% from 31.8% in individuals who had a history of improper bowel preparation.

It goes without saying that the development was a significant one and the rally in the stock is hence understandable. It may be a good time to add the Motus stock to your watch lists.

Key Quote

“We are pleased to report that topline data from the EU study show our Pure-Vu Gen2 system was able to improve the adequate cleansing rate from 31.8% to 97.7% in patients with a history of poor bowel preparation. By allowing physicians to achieve adequate cleaning, and therefore proper visualization in these difficult to prep patients, they can avoid canceled or incomplete procedures that may need to be rescheduled, which places stress on the patient and the healthcare system,” commented Tim Moran, Chief Executive Officer of Motus.

Technical Data

MOTS stock is trading above the 20-Day and 50-Day Moving averages of $0.27 and $0.31 respectively. However, the stock is trading below the 200-Day moving average of $0.50.